The global botulinum toxin market size was valued at USD 11.1 billion in 2023 and is expected to grow at a compound annual growth rate (CAGR) of 9.8% from 2024 to 2030. Botulinum toxin is a protein and neurotoxin produced by the bacterium clostridium botulinum. The toxin is a selective blocker of acetylcholine released from nerves, which blocks neural transmission from the nerves when injected into muscle. Botulinum toxin is one of the most exceptional substances encountered in medicine and science. The adoption of botulinum toxin in cosmetology has grown rapidly over the decade, and at present it is one of the most common and widely performed aesthetic procedures in the world. The increasing concern for aesthetic features in developed and developing regions has led to an increase in the number of cosmetic procedures.

The availability of a variety of botulinum toxin products such as botox, xeomin, dysport, and others will accelerate the market growth. The increasing usage of botulinum toxin injection in several aesthetic procedures including the treatment of glabellar lines, chemical browlift, forehead lines, and others is expected to boost the botulinum toxin industry growth over the coming years. Presently, a few products of botulinum toxin - Type-A and only one product of Type-B (Myobloc) are commercially available in the market.

Gather more insights about the market drivers, restrains and growth of the Global Botulinum Toxin Market

Botulinum Toxin Market Segments Highlights:

• Based on end-use, the market is segmented into hospitals, dermatology clinics, and spas & cosmetic clinics. Cosmetic centers and medspas accounted for the largest market share of 44.5% in 2023. The segment is likely to grow with a CAGR of 10.2%.
• The hospital segment accounted for a revenue share of 43.4% in 2023. Rising number of hospitals with advanced care and facilities in developed and developing countries and increasing awareness for aesthetic procedures performed attributes the segment growth.
• The botulinum toxin-type- A segment exhibited the largest revenue share of 98.8% in 2023. Botulinum toxin A is anticipated to grow at a significant rate due to rise in customer preference owing to advantages including minimal pain, no blood loss, and lack of scarring during the procedure.
• Botulinum toxin-type- A products are adopted for range of therapeutic and aesthetic applications, and with the rising demand for aesthetic beauty, the segment is likely to grow further in the near future.
• North America accounted for a significant revenue share of 46.9% in 2023 and is anticipated to reach USD 5.1 billion by 2030 owing to increasing disposable income and growing number of cosmetic procedures.
• Asia Pacific region is expected to witness the highest CAGR of 11.1% over the forecast period owing to a favorable reimbursement, large patient population, and availability of developed healthcare facilities in many countries. In countries, like South Korea, China, and Japan, there is higher beauty consciousness and aesthetic awareness, hence likely to drive the market growth.
• Based on application, botulinum toxin sector is segmented into aesthetic and therapeutic applications. The aesthetic segment is expected to witness a significant CAGR of 10.2% during the forecast period.
• The therapeutic application segment accounted for 43.0% of the market share. The therapeutic benefits of botulinum toxin have been diversifying due to deeper understanding of its different mechanisms of action and molecular behavior.

Browse through Grand View Research's Medical Devices Industry Research Reports.

• Arterial Cannula Market: The global arterial cannula market size was estimated at USD 21.8 million in 2024 and is projected to grow at a CAGR of 7.5% from 2025 to 2030.
• Sclerotherapy Market: The global sclerotherapy market size was estimated at USD 1.15 billion in 2024 and is projected to grow at a CAGR of 4.4% from 2025 to 2030.

Key Companies & Market Share Insights:

The global market is competitive in nature and is highly regulated. Major players in the industry have built key business strategies such as product innovation, new product launches, strategic partnerships & collaborations, joint ventures, advanced service launches, and contracts to create their industry position along with gaining a huge chunk of the market share.

In July 2020, Tenjin Pharma and Merz Pharma collaboratively signed up for a sale of Xeomin (incobotulinumtoxinA) of Tenjin Pharma for intramuscular injection in 50, 100 and 200 units for the treatment of lower limb spasticity and is also approved by Japan’s Ministry of Health. This strategy of the company will promote the organization to add value to its business products portfolio, thereby strengthening its revenue generation stream.

Key Botulinum Toxin Companies:

• Ipsen Group
• Allergen, Inc.
• Metabiologics
• Merz Pharma
• US Worldmeds
• Evolus
• Galderma
• Lanzhou Institute of Biological Products

Order a free sample PDF of the Botulinum Toxin Market Intelligence Study, published by Grand View Research.